heptodin lamivudine tablets chronic hbv hiv 100mg

Description

Indication & Scope

Heptodin® Lamivudine Tablets provides long-term antiviral therapy for adult chronic hepatitis B with active HBV replication and elevated liver enzymes; combination antiretroviral therapy for HIV-1 infection in adults and children.

Mechanism: A synthetic nucleoside reverse transcriptase analog. After intracellular phosphorylation, it competes with natural cytidine to incorporate into viral DNA strands, terminating DNA chain elongation and blocking replication of HBV and HIV-1. Long-term monotherapy easily induces viral gene mutation and drug resistance.
Drug class: Nucleoside reverse transcriptase inhibitor; broad-spectrum antiviral agent for HBV and HIV; prescription anti-retroviral medicine.
Clinical use: Long-term suppression of HBV replication to reduce liver inflammation and slow fibrosis for chronic hepatitis B; used as a core component of multi-drug combination regimens for HIV infection control to lower viral load.

Specification

Generic Name	Lamivudine Tablets
Brand Name	Heptodin
Ingredient	Lamivudine
Dosage Form	Tablets
Package	0.1g*14 tablets/box
Conditions Treated	Compensated chronic hepatitis B with active viral replication; HIV-1 infection used in combined antiretroviral schemes
Taboos	Severe hypersensitivity to lamivudine or any tablet excipients; simultaneous use of other medicines containing lamivudine or emtricitabine
Place of origin	China
Prescription type	Prescription-only
Storage Conditions	Sealed blister packs stored at 15°C to 30°C, kept dry, shaded, and away from high temperature and moisture
Manufacturer	YaoPharma(Chongqing) Co., Ltd.
Registration Authority	National Medical Products Administration (NMPA), China
Approval number	H20030581
Approval Date	Apr 14, 2025
Shelf Life	24 months

How to use ?

Recommended Dose: For chronic hepatitis B: 100 mg once daily for adults with normal renal function. For HIV-1 infection: 150 mg twice daily. Dosage reduction is required for patients with renal insufficiency.

Time: Fixed daily dosing intervals; administration can be performed with or without meals with no strict dietary limits.

Instructions for use: Swallow whole tablets without splitting or chewing; arbitrary early discontinuation will cause sharp viral rebound and drug resistance; regular monitoring of HBV DNA, liver function and renal function is required throughout treatment; monotherapy for long-term HBV treatment is not recommended.

Interaction: Other renally excreted antiviral drugs will affect renal clearance and require dosage adjustment; combined use with zalcitabine increases peripheral neuropathy risk; drugs inhibiting renal tubular secretion will raise blood concentration of lamivudine.

Side effects:

1. Common mild adverse reactions: headache, fatigue, mild nausea, diarrhea, transient elevated liver transaminase.

2. Rare severe adverse reactions: lactic acidosis, severe hepatomegaly with steatosis, pancreatitis, peripheral neuropathy, severe allergic reactions.

Important Notice

This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.

Packaging & Shipping

Packaging

Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.

Shipping Methods

Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.

Export Support